Journal Scans
Neoadjuvant Chemotherapy With Trastuzumab Followed by Adjuvant Trastuzumab Versus Neoadjuvant Chemotherapy Alone, in Patients With HER2-Positive Locally Advanced Breast Cancer (the NOAH Trial)
NOAH Trial of Neoadjuvant Trastuzumab in HER2+ Breast Cancer
L Gianni, W Eiermann, V Semiglazov, A Manikhas, A Lluch, S Tjulandin, M Zambetti, F Vazquez, M Byakhow, M Lichinitser, MA Climent, E Ciruelos, B Ojeda, M Mansutti, A Bozhok, R Baronio, A Feyereislova, C Barton, P Valagussa, J Baselga
Yes
20100030
2010 Jan 30
Lancet
Neoadjuvant Chemotherapy With Trastuzumab Followed by Adjuvant Trastuzumab Versus Neoadjuvant Chemotherapy Alone, in Patients With HER2-Positive Locally Advanced Breast Cancer (the NOAH Trial)
Lancet. 2010 Jan 30;375(9712):377-384, L Gianni, W Eiermann, V Semiglazov, A Manikhas, A Lluch, S Tjulandin, M Zambetti, F Vazquez, M Byakhow, M Lichinitser, MA Climent, E Ciruelos, B Ojeda, M Mansutti, A Bozhok, R Baronio, A Feyereislova, C Barton, P Valagussa, J Baselga
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
Abstract
Background: The monoclonal antibody trastuzumab has survival benefit when given with chemotherapy to patients with early, operable, and metastatic breast cancer that has HER2 (also known as ERBB2) overexpression or amplification. We aimed to assess event-free survival in patients with HER2-positive locally advanced or inflammatory breast cancer receiving neoadjuvant chemotherapy with or without 1 year of trastuzumab. Methods: We compared 1 year of treatment with trastuzumab (given as neoadjuvant...
